Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Adding context to stock valuations can significantly affect buying decisions.